Duodopa rejected for NHS use in Scotland

News

Author: Almaz OhenePublished: 11 January 2016

Prep: Cook: Serves:

The advanced Parkinson’s treatment Duodopa has been rejected for routine use on the NHS in Scotland, sparking concerns among charities and health professionals.

The Scottish Medicines Consortium (SMC) said it was unable to approve of Duodopa, due to questions raised over its cost-effectiveness.

Dr Alan MacDonald, vice chairman of SMC, said: “The Committee was unable to accept co-careldopa intestinal gel (Duodopa) for the routine treatment of advanced Parkinson’s disease because of uncertainty about the clinical benefits the medicine would provide for this patient group in relation to its cost.”

Duodopa, which can help to control the symptoms of advanced Parkinson’s when all other treatments have stopped working. The gel treatment is administered to the intestine via pump and a tube and requires the patient to undergo surgery – it is estimated to cost around £28,000-per-year per patient and was approved for use by the NHS in England in July 2015.

Last Month

Next Month

Go Back

Share this story

Comments

Interviews

‘My Dad: his Parkinson’s through my 9-year-old eyes’

We talk to the man who sketches his Parkinson’s symptoms

How these laser-guided shoes keep Parkinson’s patients on their feet

Meet the inventor of a laser-guided shoe for Parkinson’s patients

Lysette Anthony: “It’s such a relief not to have to hide it anymore”

The UK actor has revealed she is living with Parkinson’s disease

Is there a link between Parkinson’s disease and blood vessel dysfunction?

Scientists in Slovakia have investigated the link between blood vessel dysfunction and Parkinson’s – and found that dopamine agonists may have an impact. The team studied the function of the endothelium – a membrane which lines the heart and blood vessels and helps control blood fluidity – in 41 people with the condition and 41 people without. Endothelial function was then measured through a parameter that assessed how easily blood could flow through the vessels. The results showed that while more people with Parkinson’s had endothelial dysfunction compared to those without, the difference did not reach statistical significance. However, the researchers noted that the findings suggested “an association between smoking, dopamine agonists, and impaired endothelial function” in those with the condition. Outlining the study’s limitations, the team noted that more research is needed to explore this potential link.

New swab test may help with Parkinson’s disease diagnosis

Researchers at the University of Manchester, UK, have drawn on one woman’s sense of smell to develop a swab test that may be used to detect Parkinson’s. The scientists used the test to analyse sebum (a type of oily substance on the skin) in 79 people with Parkinson’s and a control group of 71 healthy individuals. The team identified more than 4,000 different compounds in the participant samples – including 500 that were unique to those living with the condition. The test was developed with the help of Joy Milne from Perth, Scotland, whose unique sense of smell meant that she noticed a change in her late husband Les’s odour twelve years before he was diagnosed with Parkinson’s. Speaking to the BBC, Professor Perdita Barran, who led the research, described the test as potentially “transformative” – and said that the team hopes to roll the test out to people in…

Could a national biobank help inform the future of Parkinson’s disease treatment in Australia?

A biobank is a collection of biological samples and data designed to be used for research. Now, researchers in Australia are working to build a biobank for Parkinson’s. As part of the project, the scientists are conducting scans of people that have been injected with fluorodopa – a substance that highlights dopamine in the brain. Participants include people living with Parkinson’s and a control group of people without the condition. The resulting database of scans will be used to create a national biobank that aims to inform treatment and research into the condition. Commenting on the study, Olivia Nasser – executive director at the Hospital Research Foundation, which is helping to fund the research – said, “Once we build up the biobank of scans, it can actually be used as an effective way to treat Parkinson’s.” The researchers encourage people with and without Parkinson’s to take part in the trial.

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Name
This field is for validation purposes and should be left unchanged.

Duodopa rejected for NHS use in Scotland

News

Author: Almaz OhenePublished: 11 January 2016

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Interviews

‘My Dad: his Parkinson’s through my 9-year-old eyes’

Interviews

How these laser-guided shoes keep Parkinson’s patients on their feet

Global update

Lysette Anthony: “It’s such a relief not to have to hide it anymore”

Is there a link between Parkinson’s disease and blood vessel dysfunction?

New swab test may help with Parkinson’s disease diagnosis

Could a national biobank help inform the future of Parkinson’s disease treatment in Australia?

{title}

Subscribe

Duodopa rejected for NHS use in Scotland

News

Author: Almaz OhenePublished: 11 January 2016

Last Month

Next Month

Share this story

Comments

Related articles

Interviews

‘My Dad: his Parkinson’s through my 9-year-old eyes’

Interviews

How these laser-guided shoes keep Parkinson’s patients on their feet

Global update

Lysette Anthony: “It’s such a relief not to have to hide it anymore”

Is there a link between Parkinson’s disease and blood vessel dysfunction?

New swab test may help with Parkinson’s disease diagnosis

Could a national biobank help inform the future of Parkinson’s disease treatment in Australia?

{title}

Subscribe

Sign in